Financing strengthens momentum as the company advances its endovascular neuromodulation platform toward first-in-human studies.
NeuroBionics today announced the completion of its oversubscribed seed round, marking significant momentum as the company advances its endovascular neuromodulation platform toward first-in-human studies. The second close was led by Future Ventures, with participation from Vanedge Capital, LionHeart Ventures, Gaingels, and Opus 44. This follows an earlier close led by Dolby Family Ventures that enabled the company to advance its clinical device and preclinical program. The combined financing brings total funding to $10M and reflects continued support from both new and existing investors.